Randomized, Double-blind, Placebo-controlled trial on Reduced Coenzyme Q10 in Parkinson Disease
- Conditions
- Parkinson disease
- Registration Number
- JPRN-UMIN000007521
- Lead Sponsor
- Department of Neurology, Juntendo University School of Medicine
- Brief Summary
Methods:Rondomized, double-blind, placebo controlled, parallel-group pilot trials were conducted to assess the efficacy of ubiquinol-10 in Japanease patients with PD. Participants were divided two groups: PD experiencing wearing off (Group A), and early PD, without levodopa (Group B). Participants took 300mg of ubiquinol-10 or placebo per day for 48 weeks (GroupA) or 96 weeks (Group B). Results: In Group A, total Unified Parkinson's Disease Rating Scale (UPDRS) scores decreased in the ubuquinol-10 group (n=14; mean+-SD [-4.2+-8.2]), indicating improvement in symptoms. There was a statistically siginificant difference (p <0.05) compared with the placebo group (n= 12;2.9+--8.9). In Group B, UPDRS increased in the ubiquinol-10 group (n=14; 3.9+-8.0), as well as in the placebo group (n=8; 5.1+--10.3). Conclusions; Ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and that ubiqionol-10 is safe and well tolerated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Not provided
1. The patietnt with parkinsonism due to corticobasal syndrome, multiple system atrophy, drug parkinsonism, hydrocephalus, essential tremor. 2. Modified Hohen-Yahr score of greater than 4. 3. The subjects had levodopa without DCI 4. The presence of other serious disease. 5. The presence of allergic response or side effects with drugs. 6. Subjects who are inappropriate for the study according to our judgment. 7. The subjects enrolled in other clinical trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method